Table 3.
The median overall survival of different molecular typing GBM after oncolytic treatments
| Generic name | rGBM mOS |
No. of patients | mOS | No. of patients | mOS | ||
|---|---|---|---|---|---|---|---|
| IDH1 | wt | mt | MGMT | met | unmet | ||
| G47Δ [10] | 20.2 |
wt:13 mt:6 |
20.9 | 19.4 |
met:2 unmet:3 NA:14 |
16.2 | 20.2 |
| PVSRIPO [30] | 11.4 |
wt:45 mt:7 NA:9 |
12.5 | 13.5 |
met:14 unmet:36 NA:11 |
14.3 | 10.4 |
| ParvOryx [33] | 11.2 |
wt:17 mt:0 NA:1 |
11.9 | – |
met:2 unmet:12 NA:4 |
11 | 8.9 |
| G207 [20] | 10.7 |
wt:10 mt:0 |
10.7 | – |
met:0 unmet:4 NA:6 |
– | 6.9 |
| DNX-2401 [22] | 9.8 |
wt:10 mt:2 NA:21 |
14.1 | 11.8 | NA:33 | – | – |
| G47Δ [12] | 7.2 |
wt:11 mt:2 |
11.6 | 6.2 |
met:7 unmet:6 |
11.6 | 6.9 |
| DNX-2401 [25] | 4.3 |
wt:15 mt:1 NA:3 |
4.3 | 93.1 | NA:19 | – | – |
wt represents wild-type; mt represents mutant-type; NA represents none identified; met represents MGMT methylation; unmet represents MGMT unmethylation